A Study to Evaluate the Effect of Metal Cation-Containing Antacids on 1200 mg QD Raltegravir Pharmacokinetics in HIV-Infected Subjects on a Stable Raltegravir-Containing Regimen.

Trial Profile

A Study to Evaluate the Effect of Metal Cation-Containing Antacids on 1200 mg QD Raltegravir Pharmacokinetics in HIV-Infected Subjects on a Stable Raltegravir-Containing Regimen.

Completed
Phase of Trial: Phase I

Latest Information Update: 31 May 2017

At a glance

  • Drugs Raltegravir (Primary) ; Aluminium hydroxide/magnesium hydroxide; Calcium carbonate
  • Indications HIV infections
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 31 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top